Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab.

ICIs can induce significant ocular side effects. As ocular inflammation can be well controlled using systemic steroids, treatment with ICIs can be continued whenever possible, in particular, if there is a good treatment response of the systemic malignancy.